Biopharmaceutical company GSK plc (LSE:GSK) (NYSE:GSK) on Wednesday raised its guidance for the full year after reporting strong growth in the second quarter.
Turnover in the three months ended 30 June 2022 amounted to GBP6.9bn, up 19% or 13% at constant exchange rates.
Vaccine sales totalled GBP1.7bn, including a record quarter for the company's shingles vaccine Shingrix which generated GBP731m in sales.
Adjusted operating profit for the second quarter was GBP2.0bn, a year-on-year increase of 22% or 7% at constant exchange rates.
GSK now expects full-year sales to grow by 6% to 8% (previously 5% to 7%), with adjusted operating profit up 13% to 15% (previously 12% to 14%), excluding COVID-19 related revenues.
(USD1=GBP0.83)
Oxford Biomedica signs extended deal to make AstraZeneca COVID-19 vaccine
Eli Lilly and Company announces Q3 2022 dividend
Abbott announces quarterly common dividend
Sun Pharma reports FY22 full year results
Alcon to expand ophthalmic eye drop portfolio with acquisition of EYSUVIS